30 closest matches · ranked by relevance
Brain Fibrillarab Levels
Primary: The Sensitivity of Blinded Visual Interpretations of [18F]Flutemetamol Positron Emission Tomography (PET) Images Without Anatomic Brain Images for Detecting Brain…
Late Onset Alzheimer Disease
Primary: Relationship Between Cognitive Change Over Time and Amyloid (Aβ) Deposition — 41; 75 Participants — p=0.02
Alzheimer Disease · Cognitive Decline
Primary: Standardized Uptake Value Ratios (SUVrs) Calculated From [18F]AV-1451 PET Scans — 1.09 standardized uptake value ratio
Metabolism - Cerebral Energy
Primary: Magnetic Resonance Spectroscopy (MRS) Will Measure a Change in Cerebral Energy Function in Brain Tissue — .011; .007; .009; .006 Difference in metabolite amplitude
Chronic Traumatic Encephalopathy
Primary: Tau Protein Uptake.. — 1.1871; 1.1652; 1.5910 SUVr
Alzheimer Disease
Primary: Change in Amyloid Burden — -1.55 dSUVR
Alzheimer's Disease
Primary: Correlation of Florbetapir-PET Image and Amyloid Plaque Density — 0.78 Correlation coefficient — p=<0.0001
Normal Pressure Hydrocephalus
Primary: Quantitative Estimates of Brain Uptake [18F]Flutemetamol and the Quantitative Immunohistochemical (IHC) Estimates of Amyloid Levels in Biopsy Samples Previously…
Alzheimer's Disease (AD)
Primary: Number of Participants With a Change of Diagnosis Comparing Pre- and Post-scan Outcomes — 137 Participants
Alzheimer's Disease
Primary: Flortaucipir Imaging (Quantitative) Between Cognitive Groups — 1.0048; 0.971; 0.9731; 0.9357 standardized uptake value ratio (SUVr)
Alzheimer Disease
Primary: Percentage of Adherence to Daily Device Use — 95.55; 95.37 percentage of adherence to treatment
Focus of Study · Coagulation Status of Cardiac Surgery Patient · Reducing Excess Blood Transfusion
Primary: Change in Thromboelastography-derived Functional Fibrinogen Level (FLEV) — -1.1 mg/dL
APOE 4
Primary: Functional Connectivity Strengths of Neural Networks — 0.233; 0.318 Pearson coefficient — p=0.007567
Alzheimer Disease
Primary: Cerebral Blood Flow Global — -2.2 ml/100g/min — p=.002
Chronic Traumatic Brain Injury
Primary: Change From Baseline of Concentrations of Essential Amino Acid at 1.5 Hours After Eating — 487.28; 553.70; 1224.19; 1339.54 µM
Alzheimer's Disease
Primary: Amyloid Deposition Obtained on a 18F-flutemetamol Brain Scan. — 1.65 ratio of flutemetamol absorbed — p=<0.05
Mild Cognitive Impairment · Alzheimer Disease
Primary: Change in Blood Neurofilament Light (NfL) Levels as Measured by Blood Biomarker Assay — 30.09; 44.25 pg/mL — p=>0.05
Mild Cognitive Impairment · Alzheimer Disease · Vascular Dementia
Primary: Percentage of Recruited Subjects Able to Comply With the Protocol — 12; 13; 3; 14 Participants
Amyloid Beta Protein
Primary: Amyloid Beta Levels in CSF — -12.7; 6.74; -22.73; -25.63 pg/mL
Alzheimer's Disease
Primary: Percent Change From Baseline to Week 12 Based on Hippocampus Connectivity Index (HCI) — 7.47 percent change
CTE · TBI (Traumatic Brain Injury)
Primary: Distribution Volume Ratio (DVR) — 1.30; 1.39; 1.26; 1.34 Distribution Volume Ratio (DVR) — p=<0.02
Primary Progressive Aphasia · Behavioral Variant of Frontotemporal Dementia · Frontotemporal Dementia, Behavioral Variant
Primary: Proportion of PPA Subjects That Showed Elevated Tau PET Binding Compared to Normal Controls — 3; 0; 17; 0 Participants
Alzheimer Disease
Primary: 18F-MK-6240 Binding — 1.41; 2.30 SUVr
Parkinson's Disease
Primary: Mean Cortical Amyloid Burden — 0.990; 1.051; 1.146 SUVR
Cerebral Amyloid Angiopathy
Primary: Change From Baseline to Day 2 in Cerebrovascular Reactivity as Measured by the Slope (Amplitude Over Time to Peak) From Visual Task-evoked Functional Magnetic Resonance…
Alzheimer's Disease · Frontotemporal Dementia
Primary: Qualitative Amyloid Image Assessment — 2; 1; 8; 4 participants
Alzheimer's Disease
Primary: Primary Outcome 1: Diagnostic Performance of Individual Readers (NFT Score) — 97.4; 68.0; 92.3; 92.0 percentage of cases correctly identified
Chronic Traumatic Encephalopathy
Primary: Flortaucipir Visual Read as CTE Biomarker — 23; 11; 5; 0 Participants — p=0.2959
Alzheimer Disease · Mild Cognitive Impairment · Neurodegenerative Diseases
Primary: Number of Participants Experiencing Treatment-emergent Adverse Events Considered Related to Florbetapir Administration — 21; 6; 5; 5 Participants
Alzheimer Disease
Primary: Number of TEAEs, Related TEAEs, SAEs, and Related SAEs — 7; 8; 6; 21 Participants